Form 4: Director William Link Acquires Shares in Tarsus Pharmaceuticals Through RSU Settlement

William Link, a director at Tarsus Pharmaceuticals, acquired 3,350 shares of common stock on June 24, 2024, through the settlement of vested Restricted Stock Units (RSUs).

Summary

• On June 24, 2024, William Link, a director of Tarsus Pharmaceuticals, acquired 3,350 shares of common stock.
• The acquisition was a result of the settlement of vested Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Tarsus Pharmaceuticals' common stock.
• Following the transaction, Link directly owns 139,982 shares of Tarsus Pharmaceuticals.
• The RSUs were granted on June 22, 2023, in connection with Link's service as a non-employee director and vested on the one-year anniversary of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to RSU vesting, which is part of standard compensation practices. There's no indication of significant positive or negative news.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive sign of confidence in the company.

Key Dates